Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference56 articles.
1. Erlanson DA, Jahnke W. In: Hubbard RE. (Ed.) Fragment-based Drug Discovery: Lessons and Outlook. Wiley-VCH Verlag GmbH & Co. KGaA, 2016; pp. 1–36.
2. What is the future for fragment-based drug discovery?
3. Fragments: past, present and future
4. Vemurafenib: the first drug approved for BRAF-mutant cancer
5. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Fragment-based drug discovery for disorders of the central nervous system: designing better drugs piece by piece;Frontiers in Chemistry;2024-04-18
2. Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening;Heliyon;2024-01
3. Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening;Journal of Medicinal Chemistry;2023-08-11
4. Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3);ACS Medicinal Chemistry Letters;2023-04-11
5. BET–HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis;Journal of Medicinal Chemistry;2023-01-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3